Literature DB >> 18592010

Gene expression signature for spontaneous cancer regression in melanoma pigs.

Florian Rambow1, Guillaume Piton, Stephan Bouet, Jean-Jaques Leplat, Sylvain Baulande, Angelique Marrau, Mark Stam, Vratislav Horak, Silvia Vincent-Naulleau.   

Abstract

Incomplete spontaneous regression of melanoma is common. However, complete melanoma regression is still a very rare phenomenon. Because melanoma is the most immunogenic human malignancy, the mechanisms leading to regression, based on accumulative evidence, are the host's immune responses. Unfortunately, therapies aiming to enhance the patient's natural immunity against melanoma have yet to meet their expectations. Reasons for failure include various immune escape mechanisms, induced by the tumor, that subsequently lead to tolerance. Here, we performed time-dependent gene expression profiling to unravel molecular changes involved in the transition of progressive melanoma to complete tumor regression using a porcine model. The melanoblastomabearing Libechov minipigs are highly suitable for this study because these animals exhibit naturally occurring and regressing melanomas. We were able to identify a molecular signature of the melanoma regression process. Genes regulated in this signature were associated with 1) cell cycle, 2) immune response, and 3) melanocyte differentiation. These genes may shed light on molecular mechanisms involved in complete melanoma regression and indicate what improvements are needed for successful antimelanoma therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18592010      PMCID: PMC2435007          DOI: 10.1593/neo.08344

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  51 in total

1.  Expression profiling of melanoma cell lines: in search of a progression-related molecular signature.

Authors:  Joost J Van den Oord; Alain Sarasin; Vèronique Winnepenninckx; Alain Spatz
Journal:  Future Oncol       Date:  2007-12       Impact factor: 3.404

2.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.

Authors:  Keith S Hoek; Natalie C Schlegel; Patricia Brafford; Antje Sucker; Selma Ugurel; Rajiv Kumar; Barbara L Weber; Katherine L Nathanson; David J Phillips; Meenhard Herlyn; Dirk Schadendorf; Reinhard Dummer
Journal:  Pigment Cell Res       Date:  2006-08

3.  Clusterin expression in primary and metastatic melanoma.

Authors:  Klaus J Busam; Derya Kucukgol; Susannah Eastlake-Wade; Denise Frosina; Ruby Delgado; Achim A Jungbluth
Journal:  J Cutan Pathol       Date:  2006-09       Impact factor: 1.587

Review 4.  Therapeutic implications of autoimmune vitiligo T cells.

Authors:  Kepa Oyarbide-Valencia; Jasper G van den Boorn; Cecele J Denman; Mingli Li; Jeremy M Carlson; Claudia Hernandez; Michael I Nishimura; Pranab K Das; Rosalie M Luiten; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2006-05-06       Impact factor: 9.754

5.  Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo.

Authors:  B Palermo; R Campanelli; S Garbelli; S Mantovani; E Lantelme; V Brazzelli; M Ardigó; G Borroni; M Martinetti; C Badulli; A Necker; C Giachino
Journal:  J Invest Dermatol       Date:  2001-08       Impact factor: 8.551

6.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

Review 7.  Divergent differentiation in malignant melanomas: a review.

Authors:  S S Banerjee; B Eyden
Journal:  Histopathology       Date:  2007-09-07       Impact factor: 5.087

Review 8.  Apoptosis of melanocytes in vitiligo results from antibody penetration.

Authors:  Alejandro Ruiz-Argüelles; Gustavo Jiménez Brito; Paola Reyes-Izquierdo; Beatriz Pérez-Romano; Sergio Sánchez-Sosa
Journal:  J Autoimmun       Date:  2007-09-20       Impact factor: 7.094

9.  Ontogeny of T lymphocytes and intestinal morphological characteristics in neonatal pigs at different ages in the postnatal period.

Authors:  D C Brown; C V Maxwell; G F Erf; M E Davis; S Singh; Z B Johnson
Journal:  J Anim Sci       Date:  2006-03       Impact factor: 3.159

10.  Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression.

Authors:  Byungwoo Ryu; Dave S Kim; Amena M Deluca; Rhoda M Alani
Journal:  PLoS One       Date:  2007-07-04       Impact factor: 3.240

View more
  14 in total

1.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

2.  Genetic and functional evaluation of MITF as a candidate gene for cutaneous melanoma predisposition in pigs.

Authors:  Emmanuelle Bourneuf; Zhi-Qiang Du; Jordi Estellé; Hélène Gilbert; Françoise Créchet; Guillaume Piton; Denis Milan; Claudine Geffrotin; Mark Lathrop; Florence Demenais; Claire Rogel-Gaillard; Silvia Vincent-Naulleau
Journal:  Mamm Genome       Date:  2011-05-28       Impact factor: 2.957

3.  p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Authors:  Stuart J Gallagher; John F Thompson; James Indsto; Lyndee L Scurr; Margaret Lett; Bo-Fu Gao; Ruth Dunleavey; Graham J Mann; Richard F Kefford; Helen Rizos
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

4.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

5.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

6.  Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.

Authors:  Ludovica Ciuffreda; Donatella Del Bufalo; Marianna Desideri; Cristina Di Sanza; Antonella Stoppacciaro; Maria Rosaria Ricciardi; Sabina Chiaretti; Simona Tavolaro; Barbara Benassi; Alfonso Bellacosa; Robin Foà; Agostino Tafuri; Francesco Cognetti; Andrea Anichini; Gabriella Zupi; Michele Milella
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

7.  Impact of a CD4 gene haplotype on the immune response in minipigs.

Authors:  Fany Blanc; Françoise Créchet; Nicolas Bruneau; Guillaume Piton; Jean-Jacques Leplat; Fabrice Andréoletti; Giorgia Egidy; Silvia Vincent-Naulleau; Emmanuelle Bourneuf
Journal:  Immunogenetics       Date:  2017-10-20       Impact factor: 2.846

8.  Treatment of Regional Metastatic Melanoma of Unknown Primary Origin.

Authors:  Elke J A H van Beek; Alfons J M Balm; Omgo E Nieweg; Olga Hamming-Vrieze; Peter J F M Lohuis; W Martin C Klop
Journal:  Cancers (Basel)       Date:  2015-08-10       Impact factor: 6.639

9.  Genome-wide Association Study to Identify Quantitative Trait Loci for Meat and Carcass Quality Traits in Berkshire.

Authors:  Asif Iqbal; You-Sam Kim; Jun-Mo Kang; Yun-Mi Lee; Rajani Rai; Jong-Hyun Jung; Dong-Yup Oh; Ki-Chang Nam; Hak-Kyo Lee; Jong-Joo Kim
Journal:  Asian-Australas J Anim Sci       Date:  2015-11       Impact factor: 2.509

10.  New susceptibility loci for cutaneous melanoma risk and progression revealed using a porcine model.

Authors:  Emmanuelle Bourneuf; Jordi Estellé; Amandine Blin; Françoise Créchet; Maria Del Pilar Schneider; Hélène Gilbert; Myriam Brossard; Amaury Vaysse; Mark Lathrop; Silvia Vincent-Naulleau; Florence Demenais
Journal:  Oncotarget       Date:  2018-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.